English 
Deutsch 
"Leitlinie standardisiert Hyperthermie in der Krebstherapie"
Hyperthermia as the Fourth Column in Oncology 
Hyperthermia Presentations/Symposia
ESTRO 2010, Barcelona
Udo Gaipl, Universitätsklinikum Erlangen
Immunological and biological rationale for hyperthermia in cancer treatment
Immunological and biological rationale for hyperthermia in cancer treatment
Martine Franckena, Erasmus Medical Center Rotterdam
Where is hyperthermia already standard in clinical practice?
Where is hyperthermia already standard in clinical practice?
Peter Wust, Charité Universitätsmedizin Berlin
Physical and technological potentials of deep RF hyperthermia
Physical and technological potentials of deep RF hyperthermia
DEGRO 2010, Magdeburg
Stephan Bodis, Kantonsspital Aarau
Innovative Hyperthermie und innovative Bestrahlung?
Innovative Hyperthermie und innovative Bestrahlung?
Martin Stuschke, Universitätsklinikum Essen
Protonen: eine universelle strahlentherapeutische Methode
Protonen: eine universelle strahlentherapeutische Methode
Stephanie Combs, Universitätsklinikum Heidelberg
Schwere Teilchen im Fokus
Schwere Teilchen im Fokus
Marco Schippers, Paul Scherrer Institut Villigen
Neue „preiswerte“ Beschleuniger?
Neue „preiswerte“ Beschleuniger?
SFRO 2009, Paris
Oliver J. Ott, Universitätsklinikum Erlangen
Evolution of clinical hyperthermia in radio-oncology
Hyperthermia and radiotherapy
Evolution of clinical hyperthermia in radio-oncology
Hyperthermia and radiotherapy
Jacoba van der Zee, Erasmus Medical Center Rotterdam
Clinical evidence of benefit by hyperthermia
Clinical evidence of benefit by hyperthermia
Gerard C. van Rhoon, Erasmus Medical Center Rotterdam
Principles of quality assurance in regional deep hyperthermia
Principles of quality assurance in regional deep hyperthermia
Gerard Devant, Salt Lake City USA
Évolution technologique de l’hyperthermie guidée par l’imagerie
Évolution technologique de l’hyperthermie guidée par l’imagerie
DEGRO 2009, Bremen
Oliver J. Ott, Universitätsklinikum Erlangen
Hyperthermia and radiation oncology: Clinical evolution
Hyperthermia and radiation oncology: Clinical evolution
Gerard C. van Rhoon, Erasmus Medical Center Rotterdam
Principles of quality assurance in regional deep hyperthermia
Principles of quality assurance in regional deep hyperthermia
Rainer Rienmüller, LKH – Universitätsklinikum Graz
MR-bound hybrid hyperthermia from a radiological point of view
MR-bound hybrid hyperthermia from a radiological point of view
Markus Thalheimer, Universitätsklinikum Heidelberg
Options for establishing hyperthermia in the German DRG system
Options for establishing hyperthermia in the German DRG system
Frederik Wenz, Universitätsklinikum Mannheim
Why hyperthermia?
Why hyperthermia?
Anneke Westermann, Academic Medical Center Amsterdam
Randomized phase III-study of chemotherapy versus chemotherapy plus hyperthermia for locally advanced cervical cancer
Randomized phase III-study of chemotherapy versus chemotherapy plus hyperthermia for locally advanced cervical cancer
ESTRO 2008, Göteborg
Michael R. Horsman, University Hospital Aarhus
Hyperthermia: a powerful enhancer of radiotherapy
Hyperthermia: a powerful enhancer of radiotherapy
Peter Wust, Charité Berlin
MR controlled online optimization of patient heat patterns
MR controlled online optimization of patient heat patterns
Oliver J. Ott, Universitätsklinikum Erlangen
Targeted hyperthermia: a powerful trigger in oncology
Evidence based clinical hyperthermia in radiation oncology
Targeted hyperthermia: a powerful trigger in oncology
Evidence based clinical hyperthermia in radiation oncology
Rolf D. Issels, Klinikum Großhadern der Universität München
Hyperthermia adds to chemotherapy
Hyperthermia adds to chemotherapy
Stefan Bodis, Kantonspital Aarau
Case presentation
Case presentation
DEGRO 2008, Wien
Ellen L. Jones, Duke University Medical Center Durham
Recent developments and results in clinical hyperthermia in the United States
Recent developments and results in clinical hyperthermia in the United States
Martine Franckena, Erasmus Medical Center Rotterdam
Long-term outcome after radiotherapy with or without hyperthermia for locally advanced cervical cancer: an 12 year update of a randomized trial
Long-term outcome after radiotherapy with or without hyperthermia for locally advanced cervical cancer: an 12 year update of a randomized trial
Johanna Gellermann, Charité Universitätsmedizin Berlin
Technical innovations in hyperthermia – intensity modulation?
Technical innovations in hyperthermia – intensity modulation?
Oliver J. Ott, Universitätsklinikum Erlangen
Hyperthermia as an integral component of multimodal treatment concepts: current development in Europe
Hyperthermia as an integral component of multimodal treatment concepts: current development in Europe
Udo Gaipl, Universitätsklinikum Erlangen
Death and immunogenicity of tumor cells after irradiation and/or hyperthermia
Death and immunogenicity of tumor cells after irradiation and/or hyperthermia
Frederik Wenz, Universitätsklinikum Mannheim
Why are we investing in hyperthermia?
Why are we investing in hyperthermia?
ESTRO 2006, Leipzig
Peter Vaupel, Universität Mainz
The biologic rationale for thermal therapy
The biologic rationale for thermal therapy
Peter Wust, Charité Berlin
The rationale, potential and state of the art of deep focused hyperthermia with and without MR monitoring
The rationale, potential and state of the art of deep focused hyperthermia with and without MR monitoring
Ellen L. Jones, Duke University Medical Center Durham
Hyperthermia in breast and ovarian cancer: recent progress and new directions
Hyperthermia in breast and ovarian cancer: recent progress and new directions
Jacoba van der Zee, Erasmus Medical Center Rotterdam
Hyperthermia in cervix and vagina cancer
Hyperthermia in cervix and vagina cancer
Oliver J. Ott, Universitätsklinikum Erlangen
Targeted hyperthermia
Bladder, prostate and rectal cancer: samples for an adjuvant role of deep focused hyperthermia
Targeted hyperthermia
Bladder, prostate and rectal cancer: samples for an adjuvant role of deep focused hyperthermia
Rüdiger Wessalowski, Universitätsklinikum Düsseldorf
Refractory high malignant soft tissue sarcoma in children and adolescents
Refractory high malignant soft tissue sarcoma in children and adolescents
April 25–26, 2013
Udo Gaipl: Immunological and biological rationale for hyperthermia in cancer treatment